{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:59:27Z","timestamp":1789761567196,"version":"4.0.1"},"reference-count":69,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background and Aims: Primary biliary cholangitis (PBC) leads to the slow, progressive destruction of the small bile ducts with consecutive cholestasis and intrahepatic cholangitis. If this disease remains untreated, liver parenchyma will be damaged resulting in fibrosis and end-stage liver disease with the need for transplantation. The approval of the Farnesoid X receptor agonist obeticholic acid (Ocaliva; OCA) in early 2017 expanded the drug therapy options of PBC, which previously consisted primarily of the administration of ursodeoxycholic acid (UDCA). Patients and Methods: Included in our prospective pilot study were 16 patients with a confirmed diagnosis of PBC who were treated with an add-on therapy with OCA (5 mg\/d). None of the patients had an overlap to autoimmune hepatitis. Patients were investigated between 09\/2022 and 09\/2023. Results: The majority of patients was female (15\/16, 93.75%), and the mean age was 57.63 \u00b1 9.59 (43\u201377) years. OCA treatment led to a statistically significant decrease in aspartate aminotransferase (AST; AST baseline: 38.50 [26.25; 50.00] IU\/L vs. AST 6-month follow-up: 23.50 [21.50; 44.25] IU\/L, p = 0.0012), alanine aminotransferase (ALT; ALT baseline: 55.50 [28.75; 97.00] IU\/L vs. ALT 6-month follow-up: 36.50 [28.00; 57.25] IU\/L, p = 0.0035), and gamma-glutamyl transferase (GGT; GGT baseline: 168.00 [100.30; 328.50] IU\/L vs. GGT 6-month follow-up: 88.00 [44.50; 259.80] IU\/L, p = 0.0063), while the decrease in alkaline phosphatase (AP) was not statistically significant (AP baseline: 197.00 [170.00; 253.30] IU\/L vs. AP 6-month follow-up: 196.00 [134.00; 227.00] IU\/L, p = 0.0915). In addition, liver stiffness measurement (LSM) showed a statistically significant decrease after six months of treatment with OCA (LSM baseline: 7.85 [5.55; 10.13] kPa vs. LSM 6-month follow-up: 5.95 [4.55; 8.225] kPa, p = 0.0001). However, the increase in enzymatic liver function measured by LiMAx failed to reach statistical significance, but showed a positive trend (LiMAx baseline: 402.50 [341.50; 469.80] \u03bcg\/kg\/h vs. LiMAx 6-month follow-up: 452.50 [412.50; 562.00] \u03bcg\/kg\/h, p = 0.0625). In none of our patients did therapy with obeticholic acid have to be stopped due to pruritus or poor tolerability. Conclusions: In patients with PBC without adequate response to UDCA, OCA is a promising alternative, which in our group of 16 patients led to a significant improvement of liver enzymes, the amelioration of liver fibrosis, and an increase in liver function capacity in a short-term clinical course.<\/jats:p>","DOI":"10.3390\/jpm15030079","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:53:06Z","timestamp":1740124386000},"page":"79","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Obeticholic Acid Improves Cholestasis, Liver Fibrosis, and Liver Function in Patients with Primary Biliary Cholangitis with Inadequate Response to Ursodeoxycholic Acid"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3394-5492","authenticated-orcid":false,"given":"Matthias","family":"Buechter","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Clinic of Essen, University of Duisburg-Essen, 45147 Essen, Germany"},{"name":"Department of Gastroenterology and Hepatology, St. Elisabeth Hospital, 58638 Iserlohn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Manka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, 44892 Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerem","family":"Bulut","sequence":"additional","affiliation":[{"name":"Clinic for Internal Medicine and Gastroenterology, St. Clemens-Hospital Geldern, 47608 Geldern, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5734-8006","authenticated-orcid":false,"given":"Guido","family":"Gerken","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Clinic of Essen, University of Duisburg-Essen, 45147 Essen, Germany"},{"name":"Department of Gastroenterology and Hepatology, Helios Clinic, 42549 Velbert, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisan","family":"Kahraman","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Clinic of Essen, University of Duisburg-Essen, 45147 Essen, Germany"},{"name":"Department of Gastroenterology and Hepatology, Max Grundig Clinic, 77815 B\u00fchl, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Fiorucci, S., Urbani, G., Di Giorgio, C., Biagioli, M., and Distrutti, E. (2024). Current Landscape and Evolving Therapies for Primary Biliary Cholangitis. Cells, 13.","DOI":"10.3390\/cells13181580"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lleo, A., Jepsen, P., Morenghi, E., Carbone, M., Moroni, L., Battezzati, P.M., Podda, M., Mackay, I.R., Gershwin, M.E., and Invernizzi, P. (2016). Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis. Sci. Rep., 6.","DOI":"10.1038\/srep25906"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1572-0241.1998.00287.x","article-title":"Autoimmune conditions associated with primary biliary cirrhosis: Response to ursodeoxycholic acid therapy","volume":"93","author":"Zukowski","year":"1998","journal-title":"Am. J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6910","DOI":"10.1097\/MS9.0000000000002672","article-title":"Elafibranor (Iqirvo) unveiled: A groundbreaking FDA-approved therapy revolutionizing primary biliary cholangitis treatment","volume":"86","author":"Ahmed","year":"2024","journal-title":"Ann. Med. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Wang, W.-L., Lian, H., Liang, Y., Ye, Y., Tam, P.K.H., and Chen, Y. (2024). Molecular Mechanisms of Fibrosis in Cholestatic Liver Diseases and Regenerative Medicine-Based Therapies. Cells, 13.","DOI":"10.3390\/cells13231997"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Yasunami, M., Nakamura, H., Tokunaga, K., Kawashima, M., Nishida, N., Hitomi, Y., and Nakamura, M. (2017). Principal contribution of HLA-DQ alleles, DQB1*06:04 and DQB1*03:01, to disease resistance against primary biliary cholangitis in a Japanese population. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-11148-6"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.29783","article-title":"Primary biliary cholangitis, DNA, and beyond: The Relative contribution of genes","volume":"68","author":"Gulamhusein","year":"2018","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.24691","article-title":"A biliary HCO3\u2212 umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes","volume":"55","author":"Hohenester","year":"2012","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.cgh.2021.08.039","article-title":"Epidemiology, Natural History, and Outcomes of Primary Sclerosing Cholangitis: A Systematic Review of Population-based Studies","volume":"20","author":"Trivedi","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/cphy.c120027","article-title":"Bile formation and secretion","volume":"3","author":"Boyer","year":"2013","journal-title":"Compr. Physiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"17562848241265782","DOI":"10.1177\/17562848241265782","article-title":"The treatment of primary biliary cholangitis: From shadow to light","volume":"17","author":"Sylvia","year":"2024","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"Hirschfield","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000493573","article-title":"Liver Maximum Capacity: A Novel Test to Accurately Diagnose Different Stages of Liver Fibrosis","volume":"100","author":"Buechter","year":"2019","journal-title":"Digestion"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.14218\/JCTH.2023.00519","article-title":"Progress in the Management of Patients with Cholestatic Liver Disease: Where Are We and Where Are We Going?","volume":"12","author":"Luo","year":"2024","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Buechter, M., and Gerken, G. (2022). Liver Function-How to Screen and to Diagnose: Insights from Personal Experiences, Controlled Clinical Studies and Future Perspectives. J. Pers. Med., 12.","DOI":"10.3390\/jpm12101657"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1111\/j.1440-1746.2010.06437.x","article-title":"Transient elastography","volume":"25","author":"Wong","year":"2010","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1477-2574.2009.00151.x","article-title":"The LiMAx test: A new liver function test for predicting postoperative outcome in liver surgery","volume":"12","author":"Stockmann","year":"2010","journal-title":"HPB"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Buechter, M., Gerken, G., Hoyer, D.P., Bertram, S., Theysohn, J.M., Thodou, V., and Kahraman, A. (2018). Liver maximum capacity (LiMAx) test as a helpful prognostic tool in acute liver failure with sepsis: A case report. BMC Anesthesiol., 18.","DOI":"10.1186\/s12871-018-0538-0"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Buechter, M., Kersting, S., Gerken, G., and Kahraman, A. (2019). Enzymatic liver function measured by LiMAx\u2014A reliable diagnostic and prognostic tool in chronic liver disease. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-49746-1"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000523696","article-title":"Performance of the Liver Maximum Function Capacity Test, Fibrinogen, and Transient Elastography in Patients with Acute Liver Injury","volume":"41","author":"Kreimeyer","year":"2023","journal-title":"Dig. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Rashidi-Alavijeh, J., Kahraman, A., Gerken, G., Theysohn, J.M., Willuweit, K., Hoyer, D.P., Lange, C.M., and Buechter, M. (2021). Enzymatic liver function measured by LiMAx is superior to current standard methods in predicting transplant-free survival after TIPS implantation. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-93392-5"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ugonabo, O., Udoh, U.-A.S., Rajan, P.K., Reeves, H., Arcand, C., Nakafuku, Y., Joshi, T., Finley, R., Pierre, S.V., and Sanabria, J.R. (2023). The Current Status of the Liver Liquid Biopsy in MASH Related HCC: Overview and Future Directions. Biomolecules, 13.","DOI":"10.3390\/biom13091369"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Gaya, A., Rohatgi, N., Limaye, S., Shreenivas, A., Ajami, R., Akolkar, D., Datta, V., Srinivasan, A., and Patil, D. (2024). Liquid Biopsy for Detection of Pancreaticobiliary Cancers by Functional Enrichment and Immunofluorescent Profiling of Circulating Tumor Cells and Their Clusters. Cancers, 16.","DOI":"10.1101\/2024.02.13.24302805"},{"key":"ref_25","first-page":"263","article-title":"Liquid biopsy in liver cancer","volume":"19","author":"Labgaa","year":"2015","journal-title":"Discov. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Mocan, T., Sim\u00e3o, A.L., Castro, R.E., Rodrigues, C.M.P., S\u0142omka, A., Wang, B., Strassburg, C., W\u00f6hler, A., Willms, A.G., and Kornek, M. (2020). Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning?. J. Clin. Med., 9.","DOI":"10.3390\/jcm9051541"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hep.32405","article-title":"Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?","volume":"76","author":"Mayo","year":"2022","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.dld.2022.12.010","article-title":"Treatment response to ursodeoxycholic acid in primary biliary cholangitis: A systematic review and meta-analysis","volume":"55","author":"Gazda","year":"2023","journal-title":"Dig. Liver Dis."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Floreani, A., Gabbia, D., and De Martin, S. (2022). Update on the Pharmacological Treatment of Primary Biliary Cholangitis. Biomedicines, 10.","DOI":"10.3390\/biomedicines10082033"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/13543784.2024.2348743","article-title":"Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis","volume":"33","author":"Akepati","year":"2024","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cgh.2017.12.033","article-title":"Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality with Treatment","volume":"16","author":"Lu","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-021-10276-6","article-title":"APASL clinical practice guidance: The diagnosis and management of patients with primary biliary cholangitis","volume":"16","author":"You","year":"2022","journal-title":"Hepatol. Int."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Deutsche Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (federf\u00fchrend), Deutsche Gesellschaft f\u00fcr Innere Medizin (DGIM), Deutsche, M. Crohn\/Colitis ulcerosa Vereinigung (DCCV), Deutsche Leberhilfe e.V., Deutsche Gesellschaft f\u00fcr Ultraschall in der Medizin (DEGUM), Deutsche Gesellschaft f\u00fcr Endoskopie und Bildgebende Verfahren (DGE-BV), Deutsche Gesellschaft f\u00fcr Kinder- und Jugendmedizin (DGKJ), Gesellschaft f\u00fcr P\u00e4diatrische Gastroenterologie (GPGE), Deutsche Gesellschaft f\u00fcr Rheumatologie (DGRh), and Deutsche R\u00f6ntgengesellschaft (DRG) (2017). S2k Leitlinie Autoimmune Lebererkrankungen [Practice guideline autoimmune liver diseases\u2014AWMF-Reg. No. 021-27]. Z. Gastroenterol., 55, 1135\u20131226.","DOI":"10.1055\/s-0043-120199"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/hep.25993","article-title":"Determination of reliability criteria for liver stiffness evaluation by transient elastography","volume":"57","author":"Boursier","year":"2013","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(24)01303-5","article-title":"Primary biliary cholangitis","volume":"404","author":"Tanaka","year":"2024","journal-title":"Lancet Lond. Engl."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.gastro.2004.05.005","article-title":"Primary biliary cirrhosis in monozygotic and dizygotic twins: Genetics, epigenetics, and environment","volume":"127","author":"Selmi","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1542-3565(04)00678-0","article-title":"From bases to basis: Linking genetics to causation in primary biliary cirrhosis","volume":"3","author":"Invernizzi","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.4049\/jimmunol.167.5.2956","article-title":"Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: Connecting xenobiotics with primary biliary cirrhosis","volume":"167","author":"Long","year":"2001","journal-title":"J. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/01.bor.0000130538.76808.c2","article-title":"Bacteria and human autoimmunity: The case of primary biliary cirrhosis","volume":"16","author":"Selmi","year":"2004","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.14309\/ajg.0000000000003174","article-title":"Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Therapy Landscape","volume":"120","author":"Bhushan","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jhep.2020.09.011","article-title":"A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA","volume":"74","author":"Hirschfield","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cld.2018.03.007","article-title":"Natural History of Primary Biliary Cholangitis in the Ursodeoxycholic Acid Era: Role of Scoring Systems","volume":"22","author":"Goel","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/17474124.2022.2153672","article-title":"Incomplete response to ursodeoxycholic acid in primary biliary cholangitis: Criteria, epidemiology, and possible mechanisms","volume":"16","author":"Huang","year":"2022","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid","volume":"130","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and Validation of a Scoring System to Predict Outcomes of Patients with Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.14309\/ajg.0000000000001280","article-title":"Ursodeoxycholic Acid Response Is Associated with Reduced Mortality in Primary Biliary Cholangitis with Compensated Cirrhosis","volume":"116","author":"John","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Zhu, H., Zheng, M., He, H., Lei, H., Tai, W., and Yang, J. (2023). High neutrophil-lymphocyte ratio indicates a worse response to ursodeoxycholic acid in primary biliary cholangitis: A retrospective cohort study. BMC Gastroenterol., 23.","DOI":"10.1186\/s12876-023-03031-8"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12072-022-10431-7","article-title":"Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: An early criterion","volume":"17","author":"Yang","year":"2023","journal-title":"Hepatol. Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S0168-8278(99)80136-6","article-title":"Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: A randomized trial","volume":"30","author":"Angulo","year":"1999","journal-title":"J. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"6691425","DOI":"10.1155\/2021\/6691425","article-title":"Ursodeoxycholic Acid at 18\u201322\u2009mg\/kg\/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis","volume":"2021","author":"Xiang","year":"2021","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cgh.2019.09.050","article-title":"Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients with Primary Biliary Cholangitis","volume":"18","author":"Bowlus","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1053\/j.gastro.2022.08.054","article-title":"Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls","volume":"163","author":"Fisher","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"8829510","DOI":"10.1155\/2021\/8829510","article-title":"Response Rate and Impact on Lipid Profiles of Obeticholic Acid Treatment for Patients with Primary Biliary Cholangitis: A Meta-Analysis","volume":"2021","author":"Gao","year":"2021","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Brookhart, M.A., Mayne, T.J., Coombs, C., Breskin, A., Ness, E., Bessonova, L., Chu, Y.J., Li, J., Fried, M.W., and Hansen, B.E. (2024). Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study design. Hepatology.","DOI":"10.1097\/HEP.0000000000001174"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/hep.32117","article-title":"Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases","volume":"75","author":"Lindor","year":"2022","journal-title":"Hepatology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1111\/liv.15379","article-title":"Predicting liver-related serious adverse events in patients with primary biliary cholangitis-related cirrhosis treated with obeticholic acid","volume":"42","year":"2022","journal-title":"Liver Int."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/HEP.0000000000000864","article-title":"Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?","volume":"80","author":"Jones","year":"2024","journal-title":"Hepatology"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Canfora, I., and Pierno, S. (2024). Hypertriglyceridemia Therapy: Past, Present and Future Perspectives. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179727"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e0005","DOI":"10.1097\/HC9.0000000000000005","article-title":"Safety and tolerability of obeticholic acid in chronic liver disease: A pooled analysis of 1878 individuals","volume":"7","author":"Ng","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"101168","DOI":"10.1016\/j.jhepr.2024.101168","article-title":"Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis","volume":"6","author":"Roberts","year":"2024","journal-title":"JHEP Rep. Innov. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1055\/a-2382-7720","article-title":"Sub-optimal therapy of patients with primary biliary cholangitis (PBC) in the real-life stetting of the German PBC cohort","volume":"62","author":"Wiegand","year":"2024","journal-title":"Z. Gastroenterol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/3\/79\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:39:21Z","timestamp":1760027961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/3\/79"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":69,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jpm15030079"],"URL":"https:\/\/doi.org\/10.3390\/jpm15030079","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]}}}